Protocol Ledger

NCT06801834 · Phase III · RECRUITING

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Interventional Phase III clinical trial protocol NCT06801834 sponsored by Gilead Sciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-04 Enrollment: 695 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06801834
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)695 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06801834
Protocol FieldVerified Registry Value
NCT IdentifierNCT06801834
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment695 participants (ESTIMATED)
Registered Start Date2025-04-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06801834
Hospital Research SiteLocationSite Profile
Southern Illinois University School of MedicineSpringfield, ILOpen Hospital Dossier ->
Springfield ClinicSpringfield, ILOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI